The MitraClip device (Abbott Vascular, Redwood City, California) is a novel percutaneous system to treat mitral regurgitation (MR). In the recent EVEREST II (Endovascular Valve Edge-to-Edge Repair Study), MitraClip therapy was compared with mitral valve (MV) surgery for moderate to severe MR (1) and despite lower efficacy revealed similar improvements in clinical outcomes.
Whereas EVEREST II reported outcomes in selected patients amenable to surgery, in this study, we assessed the outcomes of patients not amenable for surgery undergoing MitraClip implantation.
Methods

Patients. Between September 2008 and March 2010, 104
consecutive patients with moderate to severe MR were determined to be at prohibitive surgical risk by joint evaluation of a panel of cardiovascular surgeons and cardiologists and thus underwent percutaneous mitral repair. All procedures were performed by 2 experienced operators (O.F., S.B.). Patient characteristics are given in Table 1 . The patients' clinical status was significantly different in several aspects from that of EVEREST II patients ( Table 2 ). All patients included in the study provided written informed consent.
Follow-up.
Device success was pre-specified as a residual MR grade of 2ϩ or less after clip implantation. At 6 and 12 months, patients were subjected to a structured interview including the Minnesota Living with Heart Failure Questionnaire (MLHFQ), transthoracic echocardiography, a 6-min walk test, and assessment of serum N-terminal probrain natriuretic peptide (NTproBNP) levels. If a return visit was hindered by comorbidities, reevaluation was restricted to telephone follow-up. Echocardiography. MR at baseline was graded according to American Society of Echocardiography guidelines (2) . After the intervention, MR severity was assessed with the technique reported by Foster et al. (3) . A description of echocardiographic methods is available in the Online Appendix. Statistical analysis. A summary of statistical methods is given in the Online Appendix.
Results
Acute outcomes. Initial device success was achieved in 96 patients (92%), with MR grade 2ϩ present in 60 patients and MR grade 1ϩ in 36. In the remaining 8 patients, clip implantation was not achieved (n ϭ 3) or did not reduce MR to less than grade 3ϩ (n ϭ 5). A single clip was implanted in 62 patients, 2 clips were implanted in 34, and Ն2 clips were implanted in 5. The median length of hospital stay was 9 days (interquartile range: 7 to 14 days). Periprocedural complications. Chordal rupture was encountered in 3 patients and clip detachment in 2 patients. Of the former patients, 2 underwent prompt surgical MV Values are mean Ϯ SD, n (%), or median (interquartile range). ACE ϭ angiotensin-converting enzyme; ARB ϭ angiotensin II receptor blocker; CRT ϭ cardiac resynchronization therapy; EuroSCORE ϭ European System for Cardiac Operative Risk Evaluation; LV ϭ left ventricular; MLHFQ ϭ Minnesota Living With Heart Failure Questionnaire; MR ϭ mitral regurgitation; NYHA ϭ New York Heart Association. Table 2 Continuous (Fig. 1) . Surgical repair was also performed in 1 patient shortly after a failed attempt at repeat clipping. Follow-up was obtained by telephone (n ϭ 18) or clinical visit (n ϭ 63) in 81 surviving patients. New York Heart Association (NYHA) functional class had improved in 65 patients (80%), with a total of 56 patients (69%) in NYHA functional class I or II at follow-up. The 6-min walk distance improved in 41 of 55 patients (75%), MLHFQ score improved in 35 of 47 patients (74%), and NTproBNP decreased in 32 of 52 patients (62%). The overall changes in these variables from baseline to follow-up are shown in Figure 2 . Baseline MR severity did not influence any outcome measure (Online Appendix). Of note, when counting patients who died (n ϭ 15) as deteriorations, statistical significance was maintained for NYHA functional class, 6-min walk distance, and MLHFQ score, but not for NT-proBNP, in a sensitivity analysis using the sign test.
Continuous and Prevalence of Categorical Patient Variables Significantly Different From the EVEREST II Study
PATIENTS WITH FAILED INDEX PROCEDURES.
Of 8 patients with failed index procedures, 1 patient underwent MV replacement on the same day and 1 patient had surgical MV repair after 2 days (Fig. 1) . The latter patient underwent valve replacement 3 months later. Of 6 patients without immediate MV surgery, 1 patient underwent MV replacement at 49 days, and 2 patients had repeat MitraClip procedures. Both repeat interventions were failures (no clip in 1 patient, residual MR grade 3ϩ in the other), and 1 was followed by surgical valve repair 4 days later. Echocardiographic follow-up. Compared with baseline, MR grade at follow-up was significantly improved; no change in left ventricular (LV) ejection fraction was observed, yet LV end-diastolic and end-systolic volumes decreased significantly. LV forward stroke volume increased significantly, whereas total stroke volume showed a significant reduction (Table 3) . Major adverse events. Twenty-six patients (25%) died between 10 and 698 days after the intervention (median 162 days); there were 4 in-hospital deaths. Deaths were adjudicated as cardiac in 19 patients (18%).
Thirteen patients required reinterventions (13%). Repeat MitraClip procedures were performed in 8 patients and failed in 2. MV surgery was performed in 7 patients (3 repairs, 5 replacements, 1 patient with both) (Fig. 1) . Twenty-eight patients (27%) were rehospitalized for cardiac decompensation. Independent predictors of cardiac rehospitalization were a baseline LV ejection fraction Ͻ45% (odds ratio: 3.90; p ϭ 0.008) and a forward stroke volume at discharge Ͻ50 ml (odds ratio: 4.54; p ϭ 0.007).
Overall, 57 patients (55%) experienced at least 1 major adverse event (i.e., cardiac rehospitalization, reintervention, or death). Kaplan-Meier estimates of freedom from death, cardiac rehospitalization, or reintervention are shown in Figure 3 . Estimates of 1-year mortality and rehospitalization were 22% and 31%, respectively.
Baseline MR grade 4ϩ and discharge forward stroke volume Ͻ50 ml independently predicted event-free survival on multivariate analysis (Table 4) .
For a comparison of patients with functional versus degenerative MR, see the Online Appendix. Values are n (%), mean Ϯ SD, or median (interquartile range). FSV ϭ forward stroke volume; LA ϭ left atrial; other abbreviations as in Table 1 .
Changes in Echocardiographic Variables From Baseline to Follow-Up
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Discussion
Our study demonstrates that in patients with severe MR not amenable to surgery, MitraClip therapy leads to sustained reduction in MR severity and reverses ventricular remodeling. Significant clinical improvement was observed in threequarters of patients followed.
Patient population. Compared with EVEREST II, the present study population differed considerably with respect to age, comorbidities, and the prevalence of functional MR. Moreover, 80% of our patients had valve morphologies that met EVEREST II exclusion criteria (1). Nevertheless, an overall procedural success rate of 92% was achieved in our study, demonstrating the general feasibility of the procedure in patients at prohibitive surgical risk. The higher procedural success rate compared with EVEREST II may be explained by 2 factors: 1) in the present study, 2 experienced operators performed all interventions; and 2) functional MR, which tends to be easier to intervene on, was more prevalent. The rate of periprocedural complications was low, with in-hospital mortality of 3.8%; expectedly, this is higher than the 1.1% mortality in the EVEREST II population but in the 2% to 10% range reported for MV surgery in high-risk patients (4, 5) . Importantly, the severity of comorbidities exceeded not only that commonly encountered in MV surgery studies but also that reported for patients denied MV surgery (6) . Compared with EVEREST II, our patients exhibited higher NYHA functional classes, yet quantitative measures of MR severity tended to be lower, possibly because of the more advanced LV dysfunction in our patients. Thus, not only do patients with cardiomyopathy have a higher degree of functional impairment, but also the severity of mostly functional MR in these patients shows a high degree of variation, with a tendency toward underestimation in recompensated patients scheduled for intervention. Clinical outcomes. Most of the patients followed exhibited significant improvements in clinical status. NYHA
Figure 3 Event-Free Survival
Cumulative survival curves for freedom from death, reintervention, cardiac rehospitalization, and the composite endpoint of freedom from death, cardiac rehospitalization, and reintervention.
Cox Regression Analyses for Death, Cardiac Rehospitalization, or Reintervention Tables 1 and 3 .
